top of page

Galápagos CEO Paul Stoffels on the company's $3.8B cash balance and decentralized CAR-T program

  • blonca9
  • Jan 9, 2024
  • 1 min read

Paul Stoffels describes how his company's decentralized CAR-T process is designed to have a shorter 'brain-to-vein' time, and he comments on the company's substantial cash balance.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

bottom of page